Journey Medical Corporation (DERM)
Market Cap | 104.87M |
Revenue (ttm) | 80.00M |
Net Income (ttm) | -4.16M |
Shares Out | 20.01M |
EPS (ttm) | -0.31 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 89,701 |
Open | 5.35 |
Previous Close | 5.37 |
Day's Range | 5.11 - 5.52 |
52-Week Range | 1.60 - 8.11 |
Beta | 0.80 |
Analysts | Strong Buy |
Price Target | 8.50 (+62.21%) |
Earnings Date | Aug 5, 2024 |
About DERM
Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris. It also offers Zilxi, a topi... [Read more]
Full Company ProfileFinancial Performance
In 2023, DERM's revenue was $79.18 million, an increase of 7.48% compared to the previous year's $73.67 million. Losses were -$3.85 million, -87.00% less than in 2022.
Financial StatementsAnalyst Forecast
According to 3 analysts, the average rating for DERM stock is "Strong Buy." The 12-month stock price forecast is $8.5, which is an increase of 62.21% from the latest price.
News
![](https://cdn.snapi.dev/images/v1/m/2/press14-2433252.jpg)
Journey Medical Corporation to Participate in the Alliance Global Partners' (A.G.P.) Virtual Healthcare Company Showcase
SCOTTSDALE, Ariz., May 15, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or “the Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company that primarily focuses on...
![](https://cdn.snapi.dev/images/v1/0/a/press7-2428000.jpg)
Journey Medical Corporation Reports First Quarter 2024 Financial Results and Recent Corporate Highlights
New Drug Application for DFD-29 to treat rosacea accepted for U.S. FDA review; PDUFA goal date of November 4, 2024 Total revenues for the first quarter ended March 31, 2024 were $13.0 million, a 7% in...
![](https://cdn.snapi.dev/images/v1/u/b/conf11-2414621.jpg)
Journey Medical Corporation to Announce First Quarter 2024 Financial Results on May 13, 2024
Company to host conference call to discuss financial results and provide a corporate update on May 13, 2024 at 4:30 p.m. ET Company to host conference call to discuss financial results and provide a c...
![](https://cdn.snapi.dev/images/v1/g/z/press2-2404133.jpg)
Journey Medical Corporation Appoints Joseph Benesch as Chief Financial Officer
SCOTTSDALE, Ariz., May 01, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or “the Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company that primarily focuses on...
![](https://cdn.snapi.dev/images/v1/w/d/conf14-2391001.jpg)
Journey Medical Corporation to Present at the Planet MicroCap Showcase: Vegas 2024
SCOTTSDALE, Ariz., April 25, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or “the Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company that primarily focuses ...
![](https://cdn.snapi.dev/images/v1/j/u/press17-2336254.jpg)
Journey Medical Corporation Reports Full-Year 2023 Financial Results and Recent Corporate Highlights
Company generated total revenues of $79.2 million for the full year ended December 31, 2023, a 7% increase from the $73.7 million reported in 2022
![](https://cdn.snapi.dev/images/v1/7/o/press17-2328674.jpg)
Journey Medical Corporation Announces U.S. FDA Acceptance of New Drug Application for DFD-29 for the Treatment of Rosacea
Prescription Drug User Fee Act (“PDUFA”) goal date of November 4, 2024 Prescription Drug User Fee Act (“PDUFA”) goal date of November 4, 2024
![](https://cdn.snapi.dev/images/v1/r/b/conf13-2326384.jpg)
Journey Medical Corporation to Announce Year End 2023 Financial Results on March 21, 2024
Company to host conference call to discuss financial results and provide a corporate update on March 21, 2024 at 4:30 p.m. ET Company to host conference call to discuss financial results and provide a...
![](https://cdn.snapi.dev/images/v1/1/2/press18-2322087.jpg)
Journey Medical Corporation to Participate in the 36th Annual ROTH Conference
SCOTTSDALE, Ariz., March 13, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical”) (Nasdaq: DERM), a commercial-stage pharmaceutical company that primarily focuses on the selling an...
![](https://cdn.snapi.dev/images/v1/6/h/press14-2317709.jpg)
Journey Medical Corporation Announces Presentation of Data from Phase 1 Clinical Trial Assessing the Impact of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) on Microbial Flora of Healthy Adults at 2024 AAD Annual Meeting
Clinical trial achieved all three primary objectives and subjects completed 16-week treatment with no significant safety issues
![](https://cdn.snapi.dev/images/v1/7/r/press19-2218072.jpg)
Journey Medical Corporation Submits New Drug Application to FDA for DFD-29 to Treat Rosacea
If approved, DFD-29 has potential to be best-in-class and the only oral medication to address both inflammatory lesions and erythema (redness) from rosacea
![](https://cdn.snapi.dev/images/v1/q/h/press15-2213766.jpg)
Journey Medical Corporation Secures Credit Facility with SWK Holdings for up to $20 Million
Provides additional capital for general corporate purposes including funding to support the potential launch of DFD-29 Provides additional capital for general corporate purposes including funding to s...
![](https://cdn.snapi.dev/images/v1/q/4/press13-2185397.jpg)
Journey Medical Corporation Announces Successful Completion of Pre-NDA Meeting with the FDA for DFD-29 to Treat Rosacea
On track to submit a New Drug Application to the FDA for DFD-29 around year-end of 2023 On track to submit a New Drug Application to the FDA for DFD-29 around year-end of 2023
![](https://cdn.snapi.dev/images/v1/j/5/press16-2145093.jpg)
Journey Medical Corporation Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights
Company generated total net revenues of $34.5 million in the third quarter of 2023, a 101% increase from $17.2 million in the second quarter of 2023
![](https://cdn.snapi.dev/images/v1/w/h/conf17-2130218.jpg)
Journey Medical Corporation to Announce Third Quarter 2023 Financial Results on November 7, 2023
Company to host conference call to discuss financial results and provide a corporate update on November 7, 2023 at 4:30 p.m. ET Company to host conference call to discuss financial results and provide...
![](https://cdn.snapi.dev/images/v1/z/v/press9-2113093.jpg)
Journey Medical Corporation Announces Data from Bioavailability Study of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) vs. Solodyn® (Minocycline Hydrochloride Extended-Release Tablets, 105 mg)
Study demonstrated systemic exposure of DFD-29 was significantly lower than that of Solodyn (105 mg) Data presented at 43rd Annual Fall Clinical Dermatology Conference New Drug Application submission ...
![](https://cdn.snapi.dev/images/v1/h/q/press16-2051140.jpg)
Journey Medical Corporation Enters into an Exclusive License Agreement with Maruho Co., Ltd. for Qbrexza® in South Korea and Other Asian Nations
SCOTTSDALE, Ariz., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical” or “the Company”), a commercial-stage pharmaceutical company that primarily focuses ...
![](https://cdn.snapi.dev/images/v1/g/e/press12-2012925.jpg)
Journey Medical Corporation Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights
The Company generated total net revenues of $17.2 million in the second quarter of 2023, a 41% increase from $12.2 million in the first quarter of 2023
![](https://cdn.snapi.dev/images/v1/p/k/conf9-2002400.jpg)
Journey Medical Corporation to Announce Second Quarter 2023 Financial Results on August 8, 2023
Company to host conference call to discuss financial results and provide a corporate update on August 8, 2023 at 4:30 p.m. ET
![](https://cdn.snapi.dev/images/v1/j/q/conf12-1977822.jpg)
Journey Medical Corporation to Announce Second Quarter 2023 Financial Results the Week of August 7, 2023
Company to host conference call to discuss financial results and provide a corporate update the week of August 7, 2023 Company to host conference call to discuss financial results and provide a corpor...
![](https://cdn.snapi.dev/images/v1/3/d/press13-1965853.jpg)
Journey Medical Corporation Announces Positive Topline Results from its Two Phase 3 Clinical Trials (MVOR-1 and MVOR-2) Evaluating DFD-29 for the Treatment of Papulopustular Rosacea in Adults
The Phase 3 clinical trials achieved the co-primary and all secondary endpoints and subjects completed the 16-week treatment with no significant safety issues
![](https://cdn.snapi.dev/images/v1/0/q/press17-1956852.jpg)
Journey Medical Corporation Expects Topline Results from the Phase 3 Clinical Trials (MVOR-1 and MVOR-2) Evaluating DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) for the Treatment of Papulopustular Rosacea to be Announced Week of July 10, 2023
SCOTTSDALE, Ariz., July 03, 2023 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical”), a commercial-stage pharmaceutical company that primarily focuses on the selling and...
![](https://cdn.snapi.dev/images/v1/a/8/press7-1931729.jpg)
Journey Medical Corporation Announces Positive Topline Data from Phase 1 Clinical Trial Assessing the Impact of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) on Microbial Flora of Healthy Adult Subjects
Clinical trial achieved all three primary objectives and subjects completed 16-week treatment with no significant safety issues
![](https://cdn.snapi.dev/images/v1/y/o/press5-1902075.jpg)
Journey Medical Corporation Reports First Quarter 2023 Financial Results and Recent Corporate Highlights
Achieved “Last Patient Out” milestone in Phase 3 clinical program evaluating DFD-29 in May 2023 Topline data are expected in June 2023 for Phase 3 clinical program evaluating DFD-29 Company to hold co...
![](https://cdn.snapi.dev/images/v1/x/s/conf8-1899874.jpg)
Journey Medical Corporation to Announce First Quarter 2023 Financial Results on May 22, 2023
Company to host conference call to discuss financial results and provide a corporate update on May 22, 2023 at 4:30 p.m. ET Company to host conference call to discuss financial results and provide a c...